FDA official logo
GSRS logoPFDA official logo

REMVULIMORGENE AUTOLEUCEL

UNII:NKC6YR89C7
Type:INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:REMVULIMORGENE AUTOLEUCEL
GSRS Full Record:
NKC6YR89C7
i

  • Remvulimorgene Autoleucel
  • autologous peripheral blood mononuclear cells (PBMCs) obtained by apheresis and engineered into enhanced antigen presenting cells (eAPCs) by loading with five messenger RNAs (mRNAs) individually encoding human papillomavirus type 16 (HPV16) E6 protein, HPV16 E7 protein, human CD86, membrane-bound interleukin 2 (mbIL-2) and membrane-bound interleukin 12 (mbIL-12). Interleukin 2 (IL-2) and interleukin 12 (IL-12) are rendered membrane-bound (mb) by fusion to the transmembrane domain of the transferrin receptor with an interceding (G4S)3 linker. The mRNAs are delivered using a microfluidic membrane deformation technique that temporarily disrupts the cell membrane. Each mRNA comprises a 5'-cap, a synthetic 5' untranslated region containing a Kozak sequence, a coding region and a 3' untranslated region (UTR) derived from the murine alpha globin UTR. The cell population phenotype is CD45+, comprising primarily T lymphocytes (CD3+), monocytes (CD14+), natural killer (NK) cells (CD56+), and B lymphocytes (CD19+)
  • remvulimorgene autoleucel [INN]




UNII - NKC6YR89C7 | UNII Search Service